Anonymized 12-month outcome tracking on validated scales (WOMAC, EDSS, ATEC, DAS28, HbA1c, anti-TPO) for stem cell therapy patients treated in Istanbul.

Anonymized 12-month follow-ups on validated clinical scales for stem cell therapy patients treated in Istanbul. Each case is one patient's documented experience and is not a predictor of any other patient's outcome.

Knee Osteoarthritis — WOMAC (F, age band 55–64, United Kingdom)

Twelve-month structured follow-up of a UK patient with grade III bilateral knee osteoarthritis, tracked on the WOMAC Index after a Wharton's Jelly MSC program in Istanbul.

Multiple Sclerosis (Relapsing-Remitting) — EDSS (M, age band 40–49, United States)

Twelve-month EDSS follow-up for a US patient with relapsing-remitting MS who underwent an intravenous plus intrathecal Wharton's Jelly MSC protocol in Istanbul.

Autism Spectrum Disorder — ATEC (M, age 6–8, United Arab Emirates)

Twelve-month ATEC follow-up of a pediatric patient with non-verbal autism spectrum disorder following a Wharton's Jelly MSC protocol in Istanbul.

Rheumatoid Arthritis — DAS28 (F, age band 45–54, Germany)

DAS28 follow-up over 12 months for a German patient with seropositive rheumatoid arthritis treated with an intravenous Wharton's Jelly MSC autoimmune program in Istanbul.

Hashimoto's Thyroiditis — anti-TPO (F, age band 35–44, Canada)

Twelve-month tracking of anti-TPO antibody levels and TSH for a Canadian patient with Hashimoto's thyroiditis following a Wharton's Jelly MSC autoimmune protocol in Istanbul.

Type 2 Diabetes Mellitus — HbA1c (M, age band 50–59, Saudi Arabia)

Twelve-month HbA1c follow-up of a Saudi Arabian patient with type 2 diabetes treated under a Wharton's Jelly MSC metabolic protocol in Istanbul.

Visit TurkeyStemcell for more information about regenerative medicine in Istanbul, Turkey.